AIDS · 2009 · 17 citations · 17 references
Veterinary MedicineImmunologyInfectious DiseasesClinical ImmunologyImmunopathologyInflammationAntiretroviral TherapyAntiviral TherapyChronic InflammationCytokine DysregulationHuman Immunodeficiency Virus PharmacotherapyImmune DysregulationC-reactive Protein TestingCd4 T-cell DepletionD-dimer FormationHighly Active Antiretroviral TherapyHiv Antiretroviral TherapyLatex Agglutination AssaysLatex Agglutination TestsWilcoxon Signed-rank Test
OBJECTIVE: To determine the effects of interleukin (IL)-2 treatment on inflammatory and thrombotic biomarkers in chronically HIV-infected adults receiving antiretroviral therapy. METHODS: Cryopreserved plasma was evaluated retrospectively for C-reactive protein (CRP) and D-dimer at baseline, end of an IL-2 cycle, and long-term follow up from two randomized, controlled trials: 57 IL-2-naive adults receiving either three to six cycles of IL-2 as well as antiretroviral therapy (nucleoside analogues) or antiretroviral therapy alone for 12 months, and 40 IL-2-experienced adults on highly active antiretroviral therapy who either interrupted or continued therapy for 6 months after a baseline IL-2 cycle. High-sensitivity CRP (hsCRP) was measured by immunonephelometry (detection limit 0.175 mg/l) and D-dimer by latex agglutination (detection limit 0.20 mg/l). Median within-group differences and pre and post-IL-2 changes between groups were assessed via nonparametric Wilcoxon signed-rank and Mann-Whitney U-tests. Spearman's rank test was used to assess correlations between changes in hsCRP, D-dimer, and HIV-RNA viral load. RESULTS: Significant increases in hsCRP (study 1: 138.6 mg/l; study 2: 58.9 mg/l) and D-dimer (study 1: 3.1 mg/l; study 2: 0.4 mg/l, all P < 0.0001) occurred by the end of the initial IL-2 cycle, returning to baseline by the end of study. No correlations were seen between changes in hsCRP or D-dimer and HIV-RNA, CD4 T-cell count, or proliferation (Ki67 expression). No thrombotic or cardiovascular serious adverse events occurred during these study periods. CONCLUSION: IL-2 dosing caused transient increases in plasma hsCRP and D-dimer levels, regardless of HIV-RNA viral load, suggesting the possibility of increased risk for thrombotic events.
17
Katja Wolf, Dimitrios Α. Tsakiris, Rainer Weber et al. · The Journal of Infectious Diseases · 2002 · 231 citations · Full text
Veterinary Medicine, Infectious Diseases, Pharmacotherapy +16